BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Alnylam Pharmaceuticals 

300 Third Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-551-8200 Fax: 617-551-8101


View Clinical Trials from BioPharm Insight

Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR), ALN-PCS for the treatment of severe hypercholesterolemia, ALN-HPN for the treatment of refractory anemia, and ALN-APC for the treatment of hemophilia. As part of its “Alnylam 5x15TM” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in advanced stages of clinical development by the end of 2015. Alnylam has additional partner-based programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection, ALN-VSP for the treatment of liver cancers, and ALN-HTT for the treatment of Huntington’s disease.

The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. In addition, Alnylam and Isis co-founded Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics; Regulus has formed partnerships with GlaxoSmithKline and Sanofi. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, and Cell.

 Key Statistics


Web Site: Alnylam Pharmaceuticals
Symbol: ALNY



Cubist Pharmaceuticals, Inc. 

 Company News
Alnylam Pharmaceuticals (ALNY) Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 9/16/2014 8:56:52 AM
Alnylam Pharmaceuticals (ALNY) Strengthens Management Team With New Key Appointments 9/15/2014 10:13:09 AM
Alnylam Pharmaceuticals (ALNY) Broadens Pipeline With ALN-AGT, A Subcutaneously Administered Rnai Therapeutic Targeting Angiotensinogen (AGT) For The Treatment Of Hypertensive Disorders Of Pregnancy (HDP), Including Preeclampsia 9/12/2014 11:04:41 AM
John Maraganore: From "Prototypical Geek" To Skillful Alnylam Pharmaceuticals (ALNY) Chief 9/8/2014 6:32:20 AM
Alnylam Pharmaceuticals (ALNY) To Webcast Presentation At Morgan Stanley Global Healthcare Conference 9/4/2014 12:42:11 PM
Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length 8/27/2014 10:38:41 AM
Alnylam Pharmaceuticals (ALNY) Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Rnai-Mediating Double-Stranded Molecules Comprising Up To 25 Base Pairs 8/20/2014 8:36:55 AM
Alnylam Pharmaceuticals (ALNY) Reports Second Quarter 2014 Financial Results And Highlights Recent Period Activities 8/8/2014 9:08:37 AM
Alnylam Pharmaceuticals (ALNY) Receives Orphan Drug Designations In The European Union For ALN-AT3, An Rnai Therapeutic In Development For The Treatment Of Hemophilia 8/7/2014 10:35:48 AM
Alnylam Pharmaceuticals (ALNY) To Webcast Conference Call Discussing Second Quarter 2014 Financial Results 8/1/2014 8:55:45 AM